Can Cannabis Use Lower Diabetes Risks In Patients With Hepatitis C?
The more that cannabis becomes available — and the more it is used by medical patients — the more evidence and studies appear to affirm the belief that the cannabinoids found in the cannabis plant are extremely beneficial as medicine.
Marijuana is already being used to treat both chronic and acute diseases, and now evidence from a new study shows that the cannabinoids in the plant have the potential to help prevent diabetes from developing in patients who are chronically ill with hepatitis C.
Researchers looked at the role cannabis can play in preventing diabetes as part of this study, and what they found was evidence that cannabis use may help lower the risk of diabetes in these patients — independent of any clinical and socio‐behavioral factors.
This is great news for patients with chronic hepatitis C infections, who are at higher risk of developing diabetes due to a heightened risk of insulin resistance — in addition to the heightened risk of liver failure and other medical issues caused by hepatitis C.
Prior research has already shown the potential benefit of cannabis use for the prevention of diabetes and related metabolic disorders in the general population, and this new information appears to support that earlier research.
Further studies are needed, of course, to confirm whether this new evidence can hold water, but if it can, this new research could lead to a huge breakthrough in the way we treat metabolic conditions, both in chronically ill hepatitis C patients and otherwise.
Regardless, it is encouraging to see more in-depth research being done on the benefits of cannabis and the results appearing in government health publications. We look forward to seeing similar work soon on Delta 8 THC, following up on the earlier empirical evidence that we shared here.